Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

Recruiting now

Conditions studied: Nasopharyngeal Carcinoma

In brief

All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.

Key facts

Study ID

NCT04085900

Run by

Zhongshan People's Hospital, Guangdong, China

People needed

40000

Starts

2020-04-01

Expected to finish

2027-12-31

Last updated by the study team

2023-07-13

Who can join

Age: 30 and older, up to 69. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subject residents in Zhongshan City or Wuzhou City
• Subject has no medical record of nasopharyngeal carcinoma
• ECOG 0-2
• Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
• Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study.

You may not qualify if…

• Subject has heavy cardiovascular, liver or kidney disease.
• Subject has contraindications to nasopharyngeal fiberoptic endoscopy.

Where it is running

• Zhongshan People's Hospital — Zhongshan, Guangdong, China (enrolling)
• Wuzhou Red Cross Hospital — Wuzhou, Guangxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.